{"id":"W2971816470","doi":"10.1111/bjd.18484","title":"Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies","year":2019,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":36,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen's University; Probity Medical Research","funders":"Merck","keywords":"Dosing; Etanercept; Medicine; Plaque psoriasis; Psoriasis; Pharmacology; Dermatology; Internal medicine; Tumor necrosis factor alpha","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008671308,0.0008098339,0.002107564,0.0002605958,0.0002905127,0.0009538966,0.0006344077,0.0008572151,0.001755341],"category_scores_gemma":[0.004257173,0.0003248481,0.002623999,0.0004855091,0.0006799929,0.0007142128,0.000211199,0.002071497,0.0004086062],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006579192,"about_ca_system_score_gemma":0.001071599,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005514057,"about_ca_topic_score_gemma":0.001070473,"domain_scores_codex":[0.9972537,0.001598992,0.000290184,0.0002401595,0.0004151635,0.0002018617],"domain_scores_gemma":[0.9934137,0.00278759,0.00221713,0.0005722957,0.0004198078,0.0005893906],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5813287,0.02792844,0.02943771,0.002596149,0.008952327,0.0001185214,0.0004949462,0.001997527,0.0420607,0.0001659327,0.001663695,0.3032553],"study_design_scores_gemma":[0.2648053,0.6159253,0.0977172,0.0004300743,0.00605563,0.0005152668,0.0001056175,0.0009648598,0.009743267,0.0002249342,0.00344919,0.00006346712],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9783515,0.01730854,0.0008000381,0.0002608277,0.00005248371,0.001040539,0.0005143035,0.00005741857,0.001614348],"genre_scores_gemma":[0.9896173,0.006449405,0.001294956,0.000473306,0.0001771863,0.0006690215,0.0008246129,0.00002962281,0.0004645385],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008671308,"threshold_uncertainty_score":0.04585886,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02410772837681473,"score_gpt":0.2871277570869232,"score_spread":0.2630200287101084,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}